Dec 14, 2018
Grünenthal and OnDosis team up for individualised dosing of oral drugs in pain management to increase patient safety
Life science startup OnDosis signs its first global development and licensing agreement for their innovative technology. Grünenthal expands its portfolio with an innovative technology for individualised dosing.
Read moreDec 04, 2018
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.
Read moreOct 18, 2018
Introducing OnDosis, a new life science company
Based on innovative technology developed by AstraZeneca, OnDosis is a new, Gothenburg-based, life science company with the mission to simplify dosing and enable personalised administration of medicines by connecting medicines, devices and digital health to benefit patients. AstraZeneca and GU Ventures have founded OnDosis together with entrepreneurial CEO, Martin Olovsson.
Read more
Press material
Download images and logotype approved for press use here.
